Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry

The ACPMP Research Foundation Appendix Cancer/PMP Patient Registry

ACPMP's first-ever patient-powered global patient registry/natural history study collects patient and caregiver information and data to fuel clinical trials and drive breakthroughs for appendix cancer and PMP. We've invested the time and resources to make our Registry regulatory grade. Our Registry operates under active, ongoing Institutional Review Board (IRB) oversight by independent ethicists. It is powered by NORD's IAMRARE®, an industry gold standard platform built to be consistent with FDA's best thinking on natural history studies.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

The ACPMP Research Foundation Appendix Cancer/PMP Patient Registry is a global, patient-powered natural history study designed to systematically collect longitudinal information from individuals affected by appendix cancer and Pseudomyxoma Peritonei (PMP).

The primary aim of the Registry is to improve understanding of these rare diseases, including their characteristics, clinical course, treatment patterns, and progression over time. Information collected through the Registry will help characterize the population affected by appendix cancer and PMP, support the development of recommendations and standards of care, and provide a resource for researchers studying disease biology, treatment outcomes, and accelerate the discovery of new treatments.

Participants, caregivers, and other authorized representatives provide information through a series of online surveys that include a prompt for patients to upload pathology reports, genomic sequencing, ctDNA reports and other relevant medical documents. Retrospective and prospective data collected include sociodemographic information, medical and diagnostic history, treatments, disease progression, management of care, and quality of life. Participants are asked to return periodically to update their information, allowing changes in disease and patient experience to be evaluated over time.

The Registry also serves as a resource to support future research and clinical trial development. With appropriate review and approval, Registry data may be used by researchers conducting retrospective studies or designing prospective studies of novel treatments. The Registry may also facilitate communication with participants about research opportunities and clinical trials for which they may be eligible.

The Registry is sponsored and managed by the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation and is hosted on the National Organization for Rare Disorders (NORD) IAMRARE® platform. The study is conducted under Institutional Review Board (IRB) oversight and follows established procedures for the collection, management, protection, and appropriate research use of participant data.

Studietype

Observasjonsmessig

Registrering (Antatt)

10000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Pennsylvania
      • Springfield, Pennsylvania, Forente stater, 19064
        • Rekruttering
        • ACPMP
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The study population consists of individuals diagnosed with appendix cancer who meet the Registry's eligibility criteria. Participants may provide information about themselves, or information may be provided by a legally authorized representative when applicable. Designated representatives may provide retrospective information for individuals who died from appendix cancer, as permitted by the study protocol. The Registry is available online and allows eligible individuals to contribute data from locations worldwide.

Beskrivelse

Inclusion Criteria:

  • Diagnosis of appendix cancer.
  • Meets the study inclusion criteria for participation.
  • Participant or, when applicable, a legally authorized representative (LAR) is able to provide informed consent and enter information into the Registry.
  • A designated representative may provide retrospective information for an individual who died from appendix cancer, as permitted by the study protocol.

Exclusion Criteria:

  • Individuals who do not meet the study inclusion criteria.
  • Individuals for whom required informed consent cannot be obtained.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Participants with Appendix Cancer and/or Pseudomyxoma Peritonei (PMP)
Individuals diagnosed with appendix cancer and/or Pseudomyxoma Peritonei (PMP) who enroll in the ACPMP Research Foundation Appendix Cancer/PMP Patient Registry. Participants, caregivers, or authorized representatives provide health and disease-related information through online surveys and may periodically update their information over time.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Natural history and clinical course of appendix cancer and Pseudomyxoma Peritonei (PMP)
Tidsramme: Up to 5 years
Characterization of the natural history and clinical course of appendix cancer and Pseudomyxoma Peritonei (PMP) using participant- and caregiver-reported data collected through the ACPMP Patient Registry.
Up to 5 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Disease Characteristics
Tidsramme: Up to 5 years
Disease characteristics of appendix cancer and pseudomyxoma peritonei (PMP), including disease type, extent, and other participant-reported disease characteristics.
Up to 5 years
Treatment History
Tidsramme: Up to 5 years
Cancer treatment history, including surgical procedures, chemotherapy, and other treatments received for appendix cancer and PMP.
Up to 5 years
Diagnosis
Tidsramme: Up to 5 years
Characteristics and timing of diagnosis of appendix cancer and PMP, including initial diagnosis and diagnostic findings.
Up to 5 years
Disease Progression
Tidsramme: Up to 5 years
Disease progression over time, based on participant- and caregiver-reported information regarding changes in disease status.
Up to 5 years
Management of Care
Tidsramme: Up to 5 years
Changes in management of care for appendix cancer and PMP, including treatments, procedures, and changes in care over time.
Up to 5 years
Signs and Symptoms
Tidsramme: Up to 5 years
Changes in signs and symptoms associated with appendix cancer and PMP over time, based on participant- and caregiver-reported data.
Up to 5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Deborah Shelton, ACPMP
  • Studiestol: Dr. Erin P. Ward, MD, University of Utah

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. februar 2026

Primær fullføring (Antatt)

1. februar 2030

Studiet fullført (Antatt)

1. februar 2030

Datoer for studieregistrering

Først innsendt

12. august 2026

Først innsendt som oppfylte QC-kriteriene

14. august 2026

Først lagt ut (Faktiske)

17. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere